Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease.

Warø BJ, Aasly JO.

Brain Behav. 2017 Dec 7;8(1):e00858. doi: 10.1002/brb3.858. eCollection 2018 Jan.

2.

The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.

Liu SY, Wile DJ, Fu JF, Valerio J, Shahinfard E, McCormick S, Mabrouk R, Vafai N, McKenzie J, Neilson N, Perez-Soriano A, Arena JE, Cherkasova M, Chan P, Zhang J, Zabetian CP, Aasly JO, Wszolek ZK, McKeown MJ, Adam MJ, Ruth TJ, Schulzer M, Sossi V, Stoessl AJ.

Lancet Neurol. 2018 Apr;17(4):309-316. doi: 10.1016/S1474-4422(18)30032-2. Epub 2018 Feb 16.

PMID:
29456161
3.

CSF lamp2 concentrations are decreased in female Parkinson's disease patients with LRRK2 mutations.

Klaver AC, Coffey MP, Aasly JO, Loeffler DA.

Brain Res. 2018 Mar 15;1683:12-16. doi: 10.1016/j.brainres.2018.01.016. Epub 2018 Feb 3.

PMID:
29456132
4.

Combining clinical and biofluid markers for early Parkinson's disease detection.

Yu Z, Stewart T, Aasly J, Shi M, Zhang J.

Ann Clin Transl Neurol. 2017 Dec 20;5(1):109-114. doi: 10.1002/acn3.509. eCollection 2018 Jan.

5.

Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers.

Wang S, Liu Z, Ye T, Mabrouk OS, Maltbie T, Aasly J, West AB.

Acta Neuropathol Commun. 2017 Nov 22;5(1):86. doi: 10.1186/s40478-017-0492-y.

6.

Alterations in the reduced pteridine contents in the cerebrospinal fluids of LRRK2 mutation carriers and patients with Parkinson's disease.

Ichinose H, Inoue KI, Arakawa S, Watanabe Y, Kurosaki H, Koshiba S, Hustad E, Takada M, Aasly JO.

J Neural Transm (Vienna). 2018 Jan;125(1):45-52. doi: 10.1007/s00702-017-1784-x. Epub 2017 Sep 1.

PMID:
28864907
7.

H. Schrader og medarbeidere svarer.

Schrader H, Aasly J, Bøhmer T.

Tidsskr Nor Laegeforen. 2017 Aug 21;137(14-15). doi: 10.4045/tidsskr.17.0581. Print 2017 Aug 22. Norwegian. No abstract available.

PMID:
28828786
Free Article
8.

Challenges presented by Munchausen syndrome.

Schrader H, Aasly JO, Bøhmer T.

Tidsskr Nor Laegeforen. 2017 May 23;137(10):696-697. doi: 10.4045/tidsskr.17.0268. eCollection 2017 May. English, Norwegian. No abstract available.

9.

Use of advanced therapies for Parkinson's disease in Norway.

Ezat B, Pihlstrøm L, Aasly J, Tysnes OB, Egge A, Dietrichs E.

Tidsskr Nor Laegeforen. 2017 May 2;137(9):619-623. doi: 10.4045/tidsskr.16.0711. eCollection 2017 May. English, Norwegian.

10.

Increased Oxidative Stress Markers in Cerebrospinal Fluid from Healthy Subjects with Parkinson's Disease-Associated LRRK2 Gene Mutations.

Loeffler DA, Klaver AC, Coffey MP, Aasly JO, LeWitt PA.

Front Aging Neurosci. 2017 Apr 3;9:89. doi: 10.3389/fnagi.2017.00089. eCollection 2017.

11.

Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder.

Puschmann A, Fiesel FC, Caulfield TR, Hudec R, Ando M, Truban D, Hou X, Ogaki K, Heckman MG, James ED, Swanberg M, Jimenez-Ferrer I, Hansson O, Opala G, Siuda J, Boczarska-Jedynak M, Friedman A, Koziorowski D, Rudzinska-Bar M, Aasly JO, Lynch T, Mellick GD, Mohan M, Silburn PA, Sanotsky Y, Vilariño-Güell C, Farrer MJ, Chen L, Dawson VL, Dawson TM, Wszolek ZK, Ross OA, Springer W.

Brain. 2017 Jun 1;140(6):e33. doi: 10.1093/brain/awx077. No abstract available.

PMID:
28379295
12.

Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.

Wile DJ, Agarwal PA, Schulzer M, Mak E, Dinelle K, Shahinfard E, Vafai N, Hasegawa K, Zhang J, McKenzie J, Neilson N, Strongosky A, Uitti RJ, Guttman M, Zabetian CP, Ding YS, Adam M, Aasly J, Wszolek ZK, Farrer M, Sossi V, Stoessl AJ.

Lancet Neurol. 2017 May;16(5):351-359. doi: 10.1016/S1474-4422(17)30056-X. Epub 2017 Mar 20.

13.

Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease.

Brockmann K, Schulte C, Schneiderhan-Marra N, Apel A, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Bernard A, Gasser T, Marras C, Schüle B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Berg D, Maetzler W.

Eur J Neurol. 2017 Feb;24(2):427-e6. doi: 10.1111/ene.13223.

PMID:
28102045
14.

Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study.

Wang L, Heckman MG, Aasly JO, Annesi G, Bozi M, Chung SJ, Clarke C, Crosiers D, Eckstein G, Garraux G, Hadjigeorgiou GM, Hattori N, Jeon B, Kim YJ, Kubo M, Lesage S, Lin JJ, Lynch T, Lichtner P, Mellick GD, Mok V, Morrison KE, Quattrone A, Satake W, Silburn PA, Stefanis L, Stockton JD, Tan EK, Toda T, Brice A, Van Broeckhoven C, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Maraganore DM, Gasser T, Krüger R, Farrer MJ, Ross OA, Sharma M; GEOPD Consortium.

Neurobiol Aging. 2017 Jan;49:217.e1-217.e4. doi: 10.1016/j.neurobiolaging.2016.09.022. Epub 2016 Oct 6.

15.

Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism.

Puschmann A, Fiesel FC, Caulfield TR, Hudec R, Ando M, Truban D, Hou X, Ogaki K, Heckman MG, James ED, Swanberg M, Jimenez-Ferrer I, Hansson O, Opala G, Siuda J, Boczarska-Jedynak M, Friedman A, Koziorowski D, Aasly JO, Lynch T, Mellick GD, Mohan M, Silburn PA, Sanotsky Y, Vilariño-Güell C, Farrer MJ, Chen L, Dawson VL, Dawson TM, Wszolek ZK, Ross OA, Springer W.

Brain. 2017 Jan;140(1):98-117. doi: 10.1093/brain/aww261. Epub 2016 Nov 2.

16.

DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.

Trinh J, Gustavsson EK, Vilariño-Güell C, Bortnick S, Latourelle J, McKenzie MB, Tu CS, Nosova E, Khinda J, Milnerwood A, Lesage S, Brice A, Tazir M, Aasly JO, Parkkinen L, Haytural H, Foroud T, Myers RH, Sassi SB, Hentati E, Nabli F, Farhat E, Amouri R, Hentati F, Farrer MJ.

Lancet Neurol. 2016 Nov;15(12):1248-1256. doi: 10.1016/S1474-4422(16)30203-4. Epub 2016 Sep 28.

PMID:
27692902
17.

Age-Related Decrease in Heat Shock 70-kDa Protein 8 in Cerebrospinal Fluid Is Associated with Increased Oxidative Stress.

Loeffler DA, Klaver AC, Coffey MP, Aasly JO, LeWitt PA.

Front Aging Neurosci. 2016 Jul 26;8:178. doi: 10.3389/fnagi.2016.00178. eCollection 2016.

18.

Arm swing as a potential new prodromal marker of Parkinson's disease.

Mirelman A, Bernad-Elazari H, Thaler A, Giladi-Yacobi E, Gurevich T, Gana-Weisz M, Saunders-Pullman R, Raymond D, Doan N, Bressman SB, Marder KS, Alcalay RN, Rao AK, Berg D, Brockmann K, Aasly J, Waro BJ, Tolosa E, Vilas D, Pont-Sunyer C, Orr-Urtreger A, Hausdorff JM, Giladi N.

Mov Disord. 2016 Oct;31(10):1527-1534. doi: 10.1002/mds.26720.

19.

Inflammatory profile in LRRK2-associated prodromal and clinical PD.

Brockmann K, Apel A, Schulte C, Schneiderhan-Marra N, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Gasser T, Schüle B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Marras C, Berg D, Maetzler W.

J Neuroinflammation. 2016 May 24;13(1):122. doi: 10.1186/s12974-016-0588-5.

20.

DCTN1 p.K56R in progressive supranuclear palsy.

Gustavsson EK, Trinh J, Guella I, Szu-Tu C, Khinda J, Lin CH, Wu RM, Stoessl J, Appel-Cresswell S, McKeown M, Rajput A, Rajput AH, Petersen MS, Jeon BS, Aasly JO, Farrer MJ.

Parkinsonism Relat Disord. 2016 Jul;28:56-61. doi: 10.1016/j.parkreldis.2016.04.025. Epub 2016 Apr 23.

PMID:
27132499
21.

Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.

Vilas D, Shaw LM, Taylor P, Berg D, Brockmann K, Aasly J, Marras C, Pont-Sunyer C, Ríos J, Marek K, Tolosa E.

Mov Disord. 2016 Jun;31(6):906-14. doi: 10.1002/mds.26591. Epub 2016 Apr 4.

PMID:
27041685
22.

CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.

Loeffler DA, Smith LM, Coffey MP, Aasly JO, LeWitt PA.

J Neural Transm (Vienna). 2016 Mar;123(3):179-87. doi: 10.1007/s00702-015-1479-0. Epub 2015 Nov 3.

PMID:
26526034
23.

Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals.

Berge G, Lauridsen C, Sando SB, Holder DJ, Møller I, Aasly JO, Bråthen G, Savage MJ, White LR.

J Alzheimers Dis. 2016;49(2):493-502. doi: 10.3233/JAD-150234.

PMID:
26484901
24.

Erratum to: Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer's pathophysiology and susceptibility.

Sevlever D, Zou F, Ma L, Carrasquillo S, Crump MG, Culley OJ, Hunter TA, Bisceglio GD, Younkin L, Allen M, Carrasquillo MM, Sando SB, Aasly JO, Dickson DW, Graff-Radford NR, Petersen RC, Deák F; Kevin Morgan for ARUK consortium, Belbin O.

Mol Neurodegener. 2015 Sep 23;10:49. doi: 10.1186/s13024-015-0047-2.

25.

Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy.

Aasly JO, Sæther O, Johansen KK, Bathen TF, Giskeødegård GF, White LR.

Parkinsons Dis. 2015;2015:264896. doi: 10.1155/2015/264896. Epub 2015 Aug 18.

26.

Large-scale assessment of polyglutamine repeat expansions in Parkinson disease.

Wang L, Aasly JO, Annesi G, Bardien S, Bozi M, Brice A, Carr J, Chung SJ, Clarke C, Crosiers D, Deutschländer A, Eckstein G, Farrer MJ, Goldwurm S, Garraux G, Hadjigeorgiou GM, Hicks AA, Hattori N, Klein C, Jeon B, Kim YJ, Lesage S, Lin JJ, Lynch T, Lichtner P, Lang AE, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Opala G, Pihlstrøm L, Pramstaller PP, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Silburn PA, Theuns J, Tan EK, Tomiyama H, Toft M, Van Broeckhoven C, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yueh KC, Zhao Y, Gasser T, Maraganore DM, Krüger R, Sharma M; GEO-PD Consortium.

Neurology. 2015 Oct 13;85(15):1283-92. doi: 10.1212/WNL.0000000000002016. Epub 2015 Sep 9.

27.

UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo.

Mortiboys H, Furmston R, Bronstad G, Aasly J, Elliott C, Bandmann O.

Neurology. 2015 Sep 8;85(10):846-52. doi: 10.1212/WNL.0000000000001905. Epub 2015 Aug 7.

28.

Novel LRRK2 mutations in Parkinsonism.

Trinh J, Guella I, McKenzie M, Gustavsson EK, Szu-Tu C, Petersen MS, Rajput A, Rajput AH, McKeown M, Jeon BS, Aasly JO, Bardien S, Farrer MJ.

Parkinsonism Relat Disord. 2015 Sep;21(9):1119-21. doi: 10.1016/j.parkreldis.2015.07.011. Epub 2015 Jul 18. No abstract available.

PMID:
26213354
29.

Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: An international consensus statement.

Puschmann A, Brighina L, Markopoulou K, Aasly J, Chung SJ, Frigerio R, Hadjigeorgiou G, Kõks S, Krüger R, Siuda J, Wider C, Zesiewicz TA, Maraganore DM.

Parkinsonism Relat Disord. 2015 Jul;21(7):675-82. doi: 10.1016/j.parkreldis.2015.04.029. Epub 2015 May 1. Review.

PMID:
25952959
30.

Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer's pathophysiology and susceptibility.

Sevlever D, Zou F, Ma L, Carrasquillo S, Crump MG, Culley OJ, Hunter TA, Bisceglio GD, Younkin L, Allen M, Carrasquillo MM, Sando SB, Aasly JO, Dickson DW, Graff-Radford NR, Petersen RC, Deák F; Kevin Morgan for ARUK consortium, Belbin O.

Mol Neurodegener. 2015 Apr 9;10:18. doi: 10.1186/s13024-015-0015-x. Erratum in: Mol Neurodegener. 2015;10:49. Mol Neurodegener. 2015;10:49. Deák, Ferenc [added].

31.

Low muscle strength in late adolescence and Parkinson disease later in life.

Gustafsson H, Aasly J, Stråhle S, Nordström A, Nordström P.

Neurology. 2015 May 5;84(18):1862-9. doi: 10.1212/WNL.0000000000001534. Epub 2015 Apr 3.

32.

Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity.

Stewart T, Sossi V, Aasly JO, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl AJ, Wang Y, Ginghina C, Liu C, Cain KC, Auinger P, Kang UJ, Jensen PH, Shi M, Zhang J.

Acta Neuropathol Commun. 2015 Jan 31;3:7. doi: 10.1186/s40478-015-0185-3.

33.

Ataxia with vitamin e deficiency in norway.

Elkamil A, Johansen KK, Aasly J.

J Mov Disord. 2015 Jan;8(1):33-6. doi: 10.14802/jmd.14030. Epub 2015 Jan 13.

34.

Familial aggregation of Parkinson's disease in the Faroe Islands.

Petersen MS, Bech S, Nosova E, Aasly J, Farrer MJ.

Mov Disord. 2015 Apr;30(4):538-44. doi: 10.1002/mds.26132. Epub 2015 Jan 20.

PMID:
25600277
35.

Genetic variability of the retromer cargo recognition complex in parkinsonism.

Gustavsson EK, Guella I, Trinh J, Szu-Tu C, Rajput A, Rajput AH, Steele JC, McKeown M, Jeon BS, Aasly JO, Farrer MJ.

Mov Disord. 2015 Apr;30(4):580-4. doi: 10.1002/mds.26104. Epub 2014 Dec 5.

PMID:
25475142
36.

Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Agalliu I, San Luciano M, Mirelman A, Giladi N, Waro B, Aasly J, Inzelberg R, Hassin-Baer S, Friedman E, Ruiz-Martinez J, Marti-Masso JF, Orr-Urtreger A, Bressman S, Saunders-Pullman R.

JAMA Neurol. 2015 Jan;72(1):58-65. doi: 10.1001/jamaneurol.2014.1973.

37.

Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI, Alcalay RN, Marder KS, Clark LN, Gaig C, Tolosa E, Ruiz-Martínez J, Marti-Masso JF, Ferrer I, López de Munain A, Goldman SM, Schüle B, Langston JW, Aasly JO, Giordana MT, Bonifati V, Puschmann A, Canesi M, Pezzoli G, Maues De Paula A, Hasegawa K, Duyckaerts C, Brice A, Stoessl AJ, Marras C.

JAMA Neurol. 2015 Jan;72(1):100-5. doi: 10.1001/jamaneurol.2014.2704.

38.

DNAJC13 genetic variants in parkinsonism.

Gustavsson EK, Trinh J, Guella I, Vilariño-Güell C, Appel-Cresswell S, Stoessl AJ, Tsui JK, McKeown M, Rajput A, Rajput AH, Aasly JO, Farrer MJ.

Mov Disord. 2015 Feb;30(2):273-8. doi: 10.1002/mds.26064. Epub 2014 Nov 12.

PMID:
25393719
39.

Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease.

Theuns J, Verstraeten A, Sleegers K, Wauters E, Gijselinck I, Smolders S, Crosiers D, Corsmit E, Elinck E, Sharma M, Krüger R, Lesage S, Brice A, Chung SJ, Kim MJ, Kim YJ, Ross OA, Wszolek ZK, Rogaeva E, Xi Z, Lang AE, Klein C, Weissbach A, Mellick GD, Silburn PA, Hadjigeorgiou GM, Dardiotis E, Hattori N, Ogaki K, Tan EK, Zhao Y, Aasly J, Valente EM, Petrucci S, Annesi G, Quattrone A, Ferrarese C, Brighina L, Deutschländer A, Puschmann A, Nilsson C, Garraux G, LeDoux MS, Pfeiffer RF, Boczarska-Jedynak M, Opala G, Maraganore DM, Engelborghs S, De Deyn PP, Cras P, Cruts M, Van Broeckhoven C; GEO-PD Consortium.

Neurology. 2014 Nov 18;83(21):1906-13. doi: 10.1212/WNL.0000000000001012. Epub 2014 Oct 17.

40.

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.

Aasly JO, Johansen KK, Brønstad G, Warø BJ, Majbour NK, Varghese S, Alzahmi F, Paleologou KE, Amer DA, Al-Hayani A, El-Agnaf OM.

Front Aging Neurosci. 2014 Sep 25;6:248. doi: 10.3389/fnagi.2014.00248. eCollection 2014.

41.

Changes in actin dynamics and F-actin structure both in synaptoneurosomes of LRRK2(R1441G) mutant mice and in primary human fibroblasts of LRRK2(G2019S) mutation carriers.

Caesar M, Felk S, Aasly JO, Gillardon F.

Neuroscience. 2015 Jan 22;284:311-24. doi: 10.1016/j.neuroscience.2014.09.070. Epub 2014 Oct 6.

PMID:
25301747
42.

Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants.

Alcalay RN, Aasly J, Berg D, Bressman S, Brice A, Brockmann K, Chan P, Clark L, Cormier F, Corvol JC, Durr A, Facheris M, Farrer M, Foroud TM, Gasser T, Giladi N, Halter C, Lang A, Langston JW, Marras C, Marti-Masso JF, Ruiz Martinez J, Mejia-Santana H, Mirelman A, Pont-Sunyer C, Orr-Urtreger A, Raymond D, Saunders-Pullman R, Schüle B, Tanner C, Tolosa E, Urkowitz A, Vilas D, Wise A, Marder K.

Genet Med. 2014 Aug;16(8):644-5. doi: 10.1038/gim.2014.55. No abstract available.

43.

LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance.

Hentati F, Trinh J, Thompson C, Nosova E, Farrer MJ, Aasly JO.

Neurology. 2014 Aug 5;83(6):568-9. doi: 10.1212/WNL.0000000000000675. Epub 2014 Jul 9. No abstract available.

44.

Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.

Caesar M, Felk S, Zach S, Brønstad G, Aasly JO, Gasser T, Gillardon F.

Glia. 2014 Jul;62(7):1075-92. doi: 10.1002/glia.22663. Epub 2014 Mar 20.

PMID:
24652679
45.

ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease.

Medway CW, Abdul-Hay S, Mims T, Ma L, Bisceglio G, Zou F, Pankratz S, Sando SB, Aasly JO, Barcikowska M, Siuda J, Wszolek ZK, Ross OA, Carrasquillo M, Dickson DW, Graff-Radford N, Petersen RC, Ertekin-Taner N, Morgan K, Bu G, Younkin SG.

Mol Neurodegener. 2014 Mar 10;9:11. doi: 10.1186/1750-1326-9-11.

46.

Alpha-synuclein repeat variants and survival in Parkinson's disease.

Chung SJ, Biernacka JM, Armasu SM, Anderson K, Frigerio R, Aasly JO, Annesi G, Bentivoglio AR, Brighina L, Chartier-Harlin MC, Goldwurm S, Hadjigeorgiou G, Jasinska-Myga B, Jeon BS, Kim YJ, Krüger R, Lesage S, Markopoulou K, Mellick G, Morrison KE, Puschmann A, Tan EK, Crosiers D, Theuns J, Van Broeckhoven C, Wirdefeldt K, Wszolek ZK, Elbaz A, Maraganore DM; Genetic Epidemiology of Parkinson's Disease Consortium.

Mov Disord. 2014 Jul;29(8):1053-7. doi: 10.1002/mds.25841. Epub 2014 Feb 27.

47.

DNAJC13 mutations in Parkinson disease.

Vilariño-Güell C, Rajput A, Milnerwood AJ, Shah B, Szu-Tu C, Trinh J, Yu I, Encarnacion M, Munsie LN, Tapia L, Gustavsson EK, Chou P, Tatarnikov I, Evans DM, Pishotta FT, Volta M, Beccano-Kelly D, Thompson C, Lin MK, Sherman HE, Han HJ, Guenther BL, Wasserman WW, Bernard V, Ross CJ, Appel-Cresswell S, Stoessl AJ, Robinson CA, Dickson DW, Ross OA, Wszolek ZK, Aasly JO, Wu RM, Hentati F, Gibson RA, McPherson PS, Girard M, Rajput M, Rajput AH, Farrer MJ.

Hum Mol Genet. 2014 Apr 1;23(7):1794-801. doi: 10.1093/hmg/ddt570. Epub 2013 Nov 11.

48.

Progressive multifocal leukoencephalopathy in an immunocompetent patient?

Johansen KK, Torp SH, Rydland J, Aasly JO.

Case Rep Neurol. 2013 Sep 4;5(3):149-54. doi: 10.1159/000354828. eCollection 2013.

49.

Cheek cell-derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control.

Stewart T, Sui YT, Gonzalez-Cuyar LF, Wong DT, Akin DM, Tumas V, Aasly J, Ashmore E, Aro P, Ginghina C, Korff A, Zabetian CP, Leverenz JB, Shi M, Zhang J.

Neurobiol Aging. 2014 Feb;35(2):418-20. doi: 10.1016/j.neurobiolaging.2013.08.008. Epub 2013 Sep 13.

50.

Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease.

Mortiboys H, Aasly J, Bandmann O.

Brain. 2013 Oct;136(Pt 10):3038-50. doi: 10.1093/brain/awt224. Epub 2013 Sep 2.

PMID:
24000005

Supplemental Content

Support Center